The initial description of GADA is quite interesting.
Like ICA, GADA are found in 70% to 80% of individuals, with new-onset type I diabetes.
Olgularin kalan %20'sinde ise antikor sadece orta kisma karsi gelismekte ve bu kisiler klinik ozellikler bakimindan GADA (-) kisilere benzer ozellikler tasimaktadir (20).
ENDIT'de tip 1 diyabetli kisilerin birinci derece yakinlarina ICA, IAA, GADA, IA-2A testleri yapilmis, sadece ICA pozitif olanlarda 5 yil icinde diyabet gelisme riski %2,2 iken, ek olarak 1, 2 veya 3 otoantikor pozitif olmasi halinde bu oranin sirasi ile %17, %39, %70 duzeyine ciktigi saptanmistir.
In another analysis of DPT-1 data (47), the predictive values of ICA alone, GADA alone, and ICA512A alone were determined and were found to be similar: 3.
CVs for the GADA and IA-2A biochemical autoantibody assays are near 5%.
The variation of the dual-label TR-IFMA assay was measured in 20 runs (4 replicates per run) using 4 serum samples that represented different, clinically relevant concentrations of GADA and IA-2A.
We measured the observed vs calculated GADA and IA-2A concentrations in 4 different dilutions, each dilution twice in 2 replicates.
Given our previous experience of poor data replication of plasma samples from controls and patients, we excluded the TR-IFMA GADA
and ELISA IA-2A methods from the following clinical evaluation although, in general, we found no major failures during the analytical evaluation and cutoff limit determinations.
The total CVs for the GADA
time-resolved fluorometric assay were determined in 20 runs (four replicates per run), using four serum samples that represented clinically relevant GADA
The results obtained by the IA2-ab and the GADA
assays are shown in Fig.
The assay kit also included anti-human IgG; assay buffer; assay calibrators with GADA
concentrations of 25, 100, 250, 500, 1000, and 5000 arbitrary units (A2-units) per liter; positive and negative controls; and dilution sera.